ICON Public Limited Company
Financials
Valuation Metrics
ICON Public Limited Company's Market Cap is $16.44B. At end of 2025 it was $14.10B. Ranked #726 of 3,114 in US market (top 23%), #230 of 1,472 on NASDAQ (top 16%), #48 of 203 in Health Care Equipment & Services (top 24%) by Market Cap.
Investment Metrics(as of 2026-10-30)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $16.44B | US#726/3,114 Sec#48/203 |
| Revenue | $8.25B | US#639/3,114 Sec#38/203 |
| Net Income | $329M | US#1,044/3,114 Sec#54/203 |
| Total Assets | $16.40B | US#700/3,114 Sec#33/203 |
| Net Assets | $9.38B | US#443/3,114 Sec#24/203 |
| Employees | 40,200 | US#307/3,114 Sec#30/203 |
| Value | ||
| P/E | 49.98x | US#1,841/3,114 Sec#88/203 |
| P/B | 1.75x | US#917/3,114 Sec#42/203 |
| P/S | 1.99x | US#1,168/3,114 Sec#80/203 |
| EV/EBITDA | 15.26x | US#1,314/3,114 Sec#44/203 |
| FCF Yield | 8.19% | US#649/3,114 Sec#26/203 |
| Profitability | ||
| ROE | 3.51% | US#1,912/3,114 Sec#96/203 |
| ROA | 2.01% | US#1,628/3,114 Sec#100/203 |
| Op. Margin | 10.15% | US#1,558/3,114 Sec#75/203 |
| Revenue Growth | 2.01% | US#2,034/3,114 Sec#155/203 |
| Earnings Growth | -58.59% | US#1,740/3,114 Sec#92/203 |
| Financial Health | ||
| Debt Ratio | 74.88% | US#829/3,114 Sec#85/203 |
| Total Debt | $3.49B | US#864/3,114 Sec#40/203 |
| FCF | $1.35B | US#478/3,114 Sec#33/203 |
| Cash | $928M | US#726/3,114 Sec#40/203 |
| Current Ratio | 0.95x | US#2,332/3,114 Sec#190/203 |
| Net Debt/EBITDA | 2.06x | US#1,342/3,114 Sec#82/203 |
| Performance | ||
| 1Y Return | 27.84% | US#1,699/3,114 Sec#121/203 |
| 1M Return | 24.34% | US#853/3,114 Sec#82/203 |
| From 52W High | -3.51% | US#806/3,114 Sec#75/203 |
| 1Y MDD | -60.54% | US#2,732/3,114 Sec#172/203 |
| Trading | ||
| Volume | 2,531,251 shares | US#1,593/3,114 Sec#103/203 |
| Trading Value | $533M | US#598/3,114 Sec#49/203 |
| Per Share | ||
| EPS | $4.23 | US#807/3,114 Sec#43/203 |
| BPS | $120.59 | US#77/3,114 Sec#8/203 |
Company Info
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.